Allakos Inc. Blog | Talkmarkets | Page 1
No data available
No data available

People who follow this stock (6)

Latest Posts

About This Stock More About This Stock
Allakos Drops After Regeneron Eosinophilic Esophagitis Study Hits Endpoints
Article By: The Fly
Tuesday, May 26, 2020 12:17 PM EST
Shares of Allakos are lower after Regeneron Pharmaceuticals announced yesterday that Part A of a Phase 3 trial evaluating Dupixent in patients 12 years and older with eosinophilic esophagitis met both of its co-primary endpoints.
In this article: REGN, ALLK
Read

Latest Tweets for $ALLK

No tweets yet!

PARTNER HEADLINES